compounded semaglutide fda enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA has strictly clarified

Counterfeit drugs are distinct from compounded versions, which pharmacies produce under specific regulatory allowances during drug shortages

Without insurance these meds run about $1,000 a month. When the guidelines came out last year, there was criticism around the belief that they continue to emphasize weight loss over health and create unnecessary shame for kids, according to nonprofit Mental Health America

Triple GLP-1 / GIP / Glucagon Receptor Agonist (CAS 2381089-83-2) Compound Name: Research Peptide (CAS 2381089-83-2) Classification: Research Peptide Multi-Receptor Agonist Description: This compound is a synthetic research peptide that functions as a triple agonist of the glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R)

In a study of adults, average HbA1c levels decreased by: 0.6% over 12 weeks in those who used Humalog in their pump 0.3% over 12 weeks in those who used human insulin in their pump In a study of adults and teenagers ages 15 years and older, average HbA1c levels decreased by 0.3% over 12 weeks in those who used Humalog in their pump